MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126 USD | -2.66% |
|
-3.66% | +15.55% |
| 02:30pm | Merck: positive results for Keytruda in breast cancer | CF |
| 01:48pm | Merck Says Phase 3 Trial of Keytruda in Triple Negative Breast Cancer Met Overall Survival Endpoint | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
02:00pm
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.5
USD
Average target price
141.9
USD
Spread / Average Target
+9.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.55% | 328B | |
| +37.50% | 727B | |
| -7.87% | 354B | |
| -0.41% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +3.81% | 164B | |
| -2.14% | 164B | |
| -1.31% | 122B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck & Co.'s Endometrial Cancer Combo Extends Progression-free Survival in Late-stage Study
